BridgeBio Pharma BBIO Interest Paid
Interest Paid at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestPaidNet.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's interest paid.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's interest paid?
- BridgeBio Pharma (BBIO) reported interest paid of $20.32M in Q1 2026.
- How has BridgeBio Pharma's interest paid changed year-over-year?
- BridgeBio Pharma's interest paid decreased by 12.7% year-over-year, from $23.27M to $20.32M.
- What is the long-term trend for BridgeBio Pharma's interest paid?
- Over 3 years (2021 to 2024), BridgeBio Pharma's interest paid has grown at a 45.3% compound annual growth rate (CAGR), from $29.77M to $91.34M.
- What does interest paid mean?
- Cash paid to lenders for interest on debt.
- How do you interpret interest paid?
- Lower interest payments relative to debt levels suggest better credit quality or lower interest rates, while higher payments increase the cash burn rate.
- How does interest paid compare across companies?
- Varies based on the company's total debt load and prevailing market interest rates.